European Healthtech startup funding raised during Q3 2014.
In Q3 2014, 27 European Healthtech companies raised a combined €246M across 28 funding rounds, up 73.6% versus Q3 2013. UK led by capital raised, and Abbvie Biotech Ventures was the most active investor. Data as of 7 Aug 2026.
| Company | Stage | Date | Amount |
|---|---|---|---|
| Adaptimmune | Series A | Sep 2014 | €79M |
| Biocartis | Series D+ | Sep 2014 | €65M |
| Gamida Cell | Growth/Late | Aug 2014 | €26M |
| MagForce | Other | Aug 2014 |
| €14M |
| AM-Pharma | Series D+ | Sep 2014 | €12M |
| NeuroDerm | Growth/Late | Aug 2014 | €12M |
| Sophia Genetics | Series B | Jul 2014 | €10M |
| Alize Pharma | Series A | Sep 2014 | €5.0M |
| Mint Solutions | Series A | Jul 2014 | €4.4M |
| Blueprint Genetics | Other | Sep 2014 | €3.5M |
| Blueprint Genetics | Seed | Aug 2014 | €2.9M |
| Nanovi | Early VC | Sep 2014 | €2.7M |
| Biotie Therapies | Grant | Jul 2014 | €1.5M |
| Mimetas | Seed | Sep 2014 | €1.2M |
| ConceptoMed | Growth/Late | Aug 2014 | €1.1M |
